低至中等发病率国家皮肤黑色素瘤基因检测改进:2法则与3法则比较
该回顾性研究纳入2004至2015年法国1032例接受基因检测的患者,评估黑色素瘤易感基因突变频率。总体突变率为6.5%,应用3法则时升至9.3%,4法则时达18.0%。建议在法国等低至中等发病率国家采用3法则,但首个黑色素瘤发生于40岁前的家族可维持2法则。
要点
- 总体突变率6.5%,3法则下9.3%,4法则下18.0%。
- 40岁前首发黑色素瘤者,2法则下突变率12.1%,3法则下18.2%。
- 40岁前使用2法则可减少3法则漏诊的CDKN2A突变家族。
核心结论
- 建议在法国等低至中等发病率国家采用3法则推荐基因检测。
- 首个黑色素瘤发生于40岁前的家族和患者可维持2法则。
研究设计与样本
- 回顾性研究,2004至2015年于昂热和里昂大学医院开展。
- 纳入1032例接受基因检测的患者。
主要发现
- 总体突变率为67/1032例(6.5%)。
- 40岁以下使用2法则可将3法则漏诊的CDKN2A突变家族从14/43降至7/43。
关键数值与推荐
- 2法则:同一患者或一、二级亲属中有2例浸润性皮肤黑色素瘤和/或相关癌症。
- 3法则:≥3例原发性黑色素瘤或遗传相关癌症。
- 4法则:4例原发性黑色素瘤或相关癌症。
临床怎么用
- 在低至中等发病率国家,优先采用3法则筛选基因检测对象。
- 对40岁前发生首个黑色素瘤的患者或家族,可继续使用2法则。
局限性
- 回忆不确定性见于88个家族(8.5%),排除后仅撤回21例(23.8%),漏诊1例突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Genetic testing for melanoma-prone mutation in France, a country with low to moderate incidence of melanoma, is proposed in cases with 2 invasive cutaneous melanomas and/or related cancers in the same patient, or in first- or second-degree relatives (rule of 2). In preclinical studies, these rules led to disclosure of mutation(s) in more than 10% of these families, the threshold widely accepted to justify genetic testing for cancers. OBJECTIVE: To reconsider these criteria in a general population testing of patients. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective study, performed from 2004 to 2015 at Angers and Lyons University Hospitals, of a cohort of 1032 patients who underwent genetic testing. MAIN OUTCOMES AND MEASURES: Frequency of mutation in high (CDKN2A, CDK4, and BAP1) and intermediate (MITF) susceptibility genes; statistical effect of histologic subtype, age, dysplastic nevi syndrome, and associated cancers on mutation rate; and evaluation of cases with anamnestic uncertainty. RESULTS: The mutation rate was 67 of 1032 patients (6.5%). Their mean (SD) age was 54.5 (14.2) years [range, 18-89 years], and 543 (52.6%) were men. It increased to 38 of 408 patients (9.3%) when applying a rule of 3 (those with ≥3 primary melanomas or genetically related cancers) (P = .68) and to 27 of 150 patients (18.0%) with a rule of 4 (4 primary melanomas or related cancer) (P < .001). The impact of age at first melanoma was observed only in those younger than 40 years, with a rate of 32 of 263 (12.1%) (P = .12) for the rule of 2 and 22 of 121 (18.2%) (P = .001) for the rule of 3. Use of the rule of 2 in patients younger than 40 years reduced the number of missed CDKN2A-mutated-families when applying the rule of 3 from 14 of 43 to 7 of 43. Anamnestic uncertainty, found in 88 families (8.5%), if excluded, would have led us to withdraw of only 21 cases (23.8%), and only 1 mutation would have been missed. CONCLUSIONS AND RELEVANCE: We propose using the rule of 3 to recommend genetic testing in France and countries with low to moderate incidence of melanoma, except in families and patients with a first melanoma occurrence before age 40 years in whom the rule of 2 could be maintained.
引用
- Delaunay J, Martin L, Bressac-de Paillerets B, et al. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3. JAMA Dermatol. 2017. PMID: 28903138. doi:10.1001/jamadermatol.2017.2926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。